Vitamin K2 and geranylgeraniol, its side chain component, inhibited osteoclast formation in a different manner

Biochemical and Biophysical Research Communications

Volumn 314, Issue 1, 2004, Pages 24-30

  Hiruma, Yuko ^a   Nakahama, Ken Ichi ^a   Fujita, Hiroshi ^a   Morita, Ikuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

1 ,25 dihydroxyvitamin D3; Alendronate; COX 2; Geranylgeraniol; Osteoclast formation; Osteoporosis; Prostaglandin E2 (PGE2); RANKL; Risedronate; Vitamin K2 (Menatetrenone, MK4)

Indexed keywords

ACTIN; CALCITRIOL; CYCLOOXYGENASE 2; FARNOQUINONE; GERANYLGERANIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MENATETRENONE; MK 4; NITROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHONIC ACID DERIVATIVE; PROSTAGLANDIN E2; BISPHOSPHONIC ACID DERIVATIVE; DITERPENE; ISOENZYME; PROSTAGLANDIN SYNTHASE; PROTEIN SUBUNIT;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SPLEEN CELL; STROMA CELL; ANIMAL; CELL DIVISION; CELL LINE; CHEMISTRY; COCULTURE; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; HEMATOPOIETIC STEM CELL; METABOLISM; MOUSE STRAIN; PHYSIOLOGY; SPLEEN;

ANIMALS; CELL DIVISION; CELL LINE; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; DINOPROSTONE; DIPHOSPHONATES; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELLS; ISOENZYMES; MALE; MICE; MICE, INBRED STRAINS; OSTEOCLASTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN SUBUNITS; SPLEEN; VITAMIN K 2;

EID: 0347986523     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.12.051     Document Type: Article

References (30)

1. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science. 289:2000;1508-1514.
2. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet. 359:2002;2018-2026.
3. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., Wesolowski G., Russell R.G.G., Rodan G.A., Reszka A.A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA. 96:1999;133-138.
4. Roger M.J., Frith J.C., Luckman S.P., Coxon F.P., Benford H.L., Mönkkönen J., Auriola S., Chilton K.M., Russel R.G.G. Molecular mechanisms of action of bisphosphonate. Bone. 24(Suppl. 5):1999;73S-79S.
5. Coxon F.P., Helfrich M.H., Hof R.V., Sebti S., Ralston S.H., Hamilton A., Rogers M.J. Protein geranylgeranylation is required for osteoclast formation, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 15:2000;1467-1476.
6. Ito M., Amizuka N., Nakajima T., Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone. 25:1999;447-452.
7. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1955;1478-1487.
8. Van Beek E.R., Löwik C.W.G.M., Papapoulos S.E. Bisphosphonate suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonate on osteoclast precursors. Bone. 30:2002;64-70.
9. Menon R.K., Gill D.S., Thomas M., Kernoff P.B.A., Dandona P. Impaired carboxylation of osteocalcin in warfarin-treated patients. J. Clin. Endocr. Metabol. 64:1987;59-61.
10. Hauschka P.V., Carr S.A. Calcium-dependent α-helical structure in osteocalcin. Biochemistry. 21:1982;2538-2547.
11. Price P.A., Williamson M.K., Lothringer J.W. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J. Biol. Chem. 256:1981;12760-12766.
12. Price P.A., Parthemore J.G., Deftos L.J., Nishimoto S.K. New biochemical marker for bone metabolism. J. Clin. Invest. 66:1980;878-883.
13. Akiyama Y., Hara K., Ohkawa I., Tajima T. Effect of Menatetrenone on bone loss induced by Ovarietomy in rats. Jpn. J. Pharmacol. 62:1993;145-153.
14. Hara K., Akiyama Y., Tajima T., Shiraki M. Effect of Menatetrenone on prednisolone-induced bone loss in rats. Bone. 14:1993;813-818.
15. 2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J. Bone Miner. Res. 12:1997;431-438.
16. 2 inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell culture. Bone. 27:2000;769-776.
17. 2 (Menatetrenone) on osteoclast-like cell formation in mouse bone marrow cultures. Eur. J. Pharmacol. 263:1994;181-185.
18. 2 (Menatetrenone) on bone resorption may be related to its side chain. Bone. 16:1995;179-184.
19. Morita I., Sakaguchi K., Kurachi T., Murota S. Ipriflavone inhibits murine osteoclast formation in vitro. Calcif. Tissue Int. 51(Suppl. 1):1992;S7-S10.
20. Sakaguchi K., Morita I., Murota S. Relationship between the ability to support differentiation of osteoclast-like cells and adipogenesis in murine stromal cells derived from bone marrow. Prostaglandins, Leukot. Essent. Fatty Acids. 62:2000;319-327.
21. Burstone M.S. Histochemical demonstration of acid phosphatases with naphtol AS-phosphates. J. Natl. Cancer Inst. 21:1958;523-539.
22. 3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells Endocrinology. 123:1988;1504-1510.
23. Reszka A.A., Halay-Nagy J.M., Masarachia P.J., Rodan G.A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J. Biol. Chem. 274:1999;34967-34973.
24. 2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor. SXR J. Biol. Chem. 278:2003;43919-43927.
25. Kawaguchi H., Pilbeam C.C., Harrison J.R., Raisz L.G. The role of prostaglandins in the regulation of bone metabolism. Clin. Orthop. 313:1995;36-46.
26. Suzawa T., Miyaura C., Inada M., Maruyama T., Sugimito Y., Ushikubi F., Ichikawa A., Narumiya S., Suda T. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 141:2000;1554-1559.
27. 2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology. 140:1999;1927-1935.
28. Okada Y., Lorenzo J.A., Freeman A.L., Tomita M., Morham S.G., Raisz L.G., Pilbeam C.C. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 105:2000;823-832.
29. Solomon C., Kremer R., White J.H., Rhim J.S. Vitamin D resistance in RAS-transformed keratinocytes: mechanism and reversal strategies. Radiat. Res. 155(1 Pt 2):2000;156-162.
30. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13:1998;581-589.